Make your money go further for just 25p per day

More than Money: Circassia

Circassia (LON: CIR) is a rare example of a small drug maker with a plan B for when drugs trials go wrong. That plan B (use its strong commercial platform to sell respiratory drugs globally) has now landed it with a second drug approval in the US and a label expansion which leaves its first US drug as the best-in-class for patients with chronic obstructive pulmonary disease (COPD). It has been ten months since Circassia filed for approval and the group’s chief executive Steve Harris was all ready to enjoy a well-earned holiday when both approvals came through on Friday. But he was still able to take some time out from his break to talk me through the good news.

Sign up for more great content

Register to continue reading our content.

Get FREE access now

Already a member? Login

Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world


Become a Champion Investor for just £90 a year.


More on Circassia

More than Money: Circassia

01/04/2019 · Podcasts
Circassia (LON: CIR) is a rare example of a small drug maker with a plan B…

February 2019: another poor month for AIM newcomers

06/03/2019 · Company Insights
With Brexit fears continuing to cast a shadow over financial markets, February 2019 was another disappointing…

More Podcasts

More than Money: Harvey Sinclair

03/03/2020 · eEnergy

More than Money: Andrew Vaughan


More than Money: Ben Crawford

19/02/2020 · CentralNic